The cost and value of cancer medicines in Ontario, Canada

Lancet Oncol. 2024 Apr;25(4):412-413. doi: 10.1016/S1470-2045(24)00099-8.
No abstract available

MeSH terms

  • Canada
  • Cost-Benefit Analysis
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / epidemiology
  • Ontario